Moonwalk Biosciences Announces $70 Million Series B: NYSE Content Update
Moonwalk Biosciences Announces $70 Million Series B: NYSE Content Update
PR Newswire
NEW YORK, Sept. 9, 2026
NYSE issues a pre-market daily advisory direct from the trading floor.
NEW YORK, Sept. 9, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.
Kristen Scholer delivers the pre-market update on September 9th
- Moonwalk Bio says recent funding will advance RNAi development.
- The startup says its treatments have demonstrated reductions in body weight and fat mass while preserving lean muscle mass.
- Moonwalk's lead development candidate is expected to enter first-in-human clinical studies in late 2027.
- CEO Dr. Alex Aravanis will join NYSE Live to discuss the path forward for treatments.
- Defense company Covenant opens a 105,000 square-foot factory in Texas.
- The company introduced Anthem, a heavy-payload, long-range weapon system.
- Covenant announced more than $250 million in funding across three rounds, with Andreesen Horowitz and Lightspeed among its backers.
- ICE Brent Crude tops $100 a barrel amid the ongoing Middle East conflict.
- This marks the first time the benchmark has reached triple digits since July.
- The rise in oil prices comes ahead of a pair of inflation reading, which are set to come out later this week.
Opening Bell
Oracle (NYSE: ORCL) brings together customers for a unique experience
Closing Bell
LabCorp (NYSE: LH) celebrates 35 years as a listed company
For market insights, IPO activity, and today's opening bell, download the NYSE TV App and check out the NYSE YouTube: TV.NYSE.com and YouTube.com/@NYSEofficial
SOURCE New York Stock Exchange
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States